GSK plc (LON:GSK) Announces GBX 15 Dividend

GSK plc (LON:GSK) declared a dividend on Wednesday, October 30th,Upcoming Dividends.Co.Uk reports. Shareholders of record on Thursday, November 14th will be given a dividend of GBX 15 ($0.19) per share on Thursday, January 9th. This represents a yield of 1.03%. The ex-dividend date of this dividend is Thursday, November 14th. The official announcement can be viewed at this link.

GSK Trading Down 2.3 %

Shares of GSK stock opened at GBX 1,364.50 ($17.56) on Tuesday. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04. The firm has a market cap of £55.67 billion, a P/E ratio of 1,207.08, a PEG ratio of 1.24 and a beta of 0.31. The company has a 50 day moving average of GBX 1,512.80 and a 200-day moving average of GBX 1,583.74. GSK has a 12-month low of GBX 1,352.86 ($17.41) and a 12-month high of GBX 1,823.50 ($23.47).

Insider Transactions at GSK

In other GSK news, insider Jonathan Symonds purchased 7,150 shares of GSK stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of GBX 1,394 ($17.94) per share, for a total transaction of £99,671 ($128,260.20). In related news, insider Elizabeth (Liz) McKee Anderson purchased 446 shares of GSK stock in a transaction that occurred on Monday, September 23rd. The shares were bought at an average price of GBX 2,051 ($26.39) per share, for a total transaction of £9,147.46 ($11,771.28). Also, insider Jonathan Symonds acquired 7,150 shares of the stock in a transaction on Wednesday, October 30th. The stock was bought at an average price of GBX 1,394 ($17.94) per share, with a total value of £99,671 ($128,260.20). 1.61% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have issued reports on GSK shares. Shore Capital restated a “buy” rating on shares of GSK in a research note on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 1,850 ($23.81) price target on shares of GSK in a research report on Tuesday, September 3rd. Berenberg Bank restated a “buy” rating and issued a GBX 1,820 ($23.42) target price on shares of GSK in a research note on Tuesday, September 10th. Finally, JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Monday, July 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, GSK has an average rating of “Moderate Buy” and a consensus price target of GBX 1,842.50 ($23.71).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.